Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EIKN
Strong SellEikon Therapeutics, Inc. · Healthcare · United States · $604M · Avg Vol: $4M/d
COMPANY DESCRIPTION
Eikon Therapeutics, Inc. is a biotechnology company focused on discovering and developing novel small molecule therapies for oncology and immunology. The company's competitive edge lies in its proprietary Eikon Explorer platform, a live-cell imaging technology that visualizes protein dynamics in real-time, significantly enhancing drug discovery and target validation. It operates as a clinical-stage biotech firm, leveraging this cutting-edge technology to accelerate the development of precision medicines.
FINANCIAL SUMMARY (USD)
| Year | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -7.40 | -7.45 | -6.18 | — | -5.95 | -6.41 | -6.33 | — |
| Shares | 54.0M | 54.0M | 54.0M | 0.0% | 54.2M | — | — | — |
| Debt | 31.7M | 202.5M | 257.3M | 184.8% | 252.2M | — | — | — |
| Equity | -341.4M | -571.9M | -879.0M | — | — | — | — | — |
| Op CF | -190.8M | -134.8M | -188.5M | — | -256.0M | — | — | — |
| Inv CF | 136.9M | 151.3M | -181.3M | — | — | — | — | — |
| Fin CF | 105.8M | 0.2M | 352.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EIKN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EIKN | Eikon Therapeutics, Inc.(you) | $604M | 10 | Strong Sell |
| ALLO | Allogene Therapeutics, Inc. | $701M | 9 | Strong Sell |
| RGNX | REGENXBIO Inc. | $532M | 12 | Strong Sell |
| SPRY | ARS Pharmaceuticals, Inc. | $532M | 8 | Strong Sell |
| KYTX | Kyverna Therapeutics, Inc. | $510M | 12 | Strong Sell |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $733M | 12 | Strong Sell |
| EVMN | Evommune, Inc. | $496M | 9 | Strong Sell |
| CTMX | CytomX Therapeutics, Inc. | $717M | 12 | Strong Sell |
| BLSM | BlossomHill Therapeutics, Inc. | $466M | 9 | Strong Sell |
| CABA | Cabaletta Bio, Inc. | $526M | 14 | Strong Sell |
Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.8%